Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis

ackground & Aim: Novel biological therapies in Crohn’s disease (CD) or Ulcerative colitis (UC) require a proper follow-up for the assessment of bowel inflammation. While endoscopy is the standard method, the imaging techniques using contrast, particularly contrast enhanced ultrasonography (CEUS), are better tolerated by the patients and can be used more frequently. Our aim was to find the usefulness of dynamic CEUS quantification as compared to endoscopy in the assessment of disease activity and in the follow-up under therapy of the patients suffering from either CD or UC. Method: We have prospectively evaluated 67 patients with UC and 46 with CD, diagnosed by ileo-colonoscopy and biopsy, comparing the endoscopic scores with clinical scores, C reactive protein (CRP), intestinal wall thickness, layer scores after CEUS and TIC parameters (using SonoLiver® software – Imax, RT, TTP, mTT and AUC). For 25 patients with UC and 13 with CD we performed comparisons of the parameters before and after 3 months of treatment and correlated them with the changes in the endoscopic scores. Results: For UC, time-intensity curves (TIC) volume parameters (AUC) correlated better with endoscopy (ρ=0.64) than the clinical score (ρ =0.62). Other parameters such as CRP and thickness showed significant but less strong correlation, while TIC flow parameters (RT, TTP and mTT) did not show a significant correlation. Results were similar for CD (ρ=0.64 for Imax vs ρ=0.58 for CDAI). The best predictor for endoscopic improvement in both UC and CD was ln(AUC), with a Wilcoxon Z score of 3.76 and 2.61, respectively. There was also a good correlation between the difference of its values and the difference in endoscopic scores before and after the treatment (rho is 0.68 in UC and 0.73 in CD). Abbreviations: CD: Crohn’s disease; CDAI: Crohn‘s disease activity index; CDEIS: Crohn‘s disease endoscopic index of severity; CEUS: Contrast-enhanced ultrasonography; CICDA: Composite index of CD activity; CRP: C-reactive protein; IBD: Inflammatory bowel disease; Imax: Maximum intensity; ln(AUC): Natural logarithm of AUC; MPI: Maximum peak intensity; mTT: Mean transit time; ROI: Region of interest; RT: Rise time; SES-CD: Simple endoscopic score for Crohn‘s disease; TIC:

Download Full-text

P473 Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjz203.602 ◽

2020 ◽

Vol 14 (Supplement_1) ◽

pp. S416-S416 ◽

Cited By ~ 1

Author(s):

C Padilla Suarez ◽

K Webb ◽

N Persad ◽

J Sercombe ◽

E Tyler ◽

...

Keyword(s):

Ulcerative Colitis ◽

Crohn’S Disease ◽

Crohn's Disease ◽

C Reactive Protein ◽

Drug Levels ◽

Reactive Protein ◽

Loss Of Response ◽

Mayo Score

Abstract Background Studies have reported good efficacy outcomes for patients with inflammatory bowel disease (IBD) treated with biosimilars. There are limited long-term data. We assessed the long-term efficacy data and safety after switching from adalimumab to adalimumab biosimilars in patients with IBD. Methods A prospective single-centre observational study involving patients with Crohn’s disease or ulcerative colitis switched from adalimumab to adalimumab biosimilar and reviewed up to 12months. Efficacy and loss of response were measured using the Harvey–Bradshaw (HB) index and partial Mayo score for patients with Crohn’s disease and ulcerative colitis respectively. Blood tests including C-reactive protein, adalimumab drug levels and anti-drug antibodies were monitored. We have recorded side effects and possible serious adverse effects. The plan is to continue the study for 24 months. Results 109 patients with IBD have completed at least 6 months of treatment with adalimumab biosimilar, 12 of which have ulcerative colitis and 97 Crohn’s disease. Most of them (88%) continued on biosimilar after 6 months. Patients discontinued the therapy due to loss of response or development of antibodies in one case. Two patients were switched to a different biosimilar due to the presence of side effects which were however not serious. Of those who remained on the treatment, 74.5% were in clinical remission at 6 months and 71.4% at 9 months. HB index, partial Mayo score, C-reactive protein and adalimumab drug levels did not show significant changes. We have not reported any serious adverse events. We hope than by February, at least 60% of these patients will have been on Adalimumab for 12 months and further amended date would be added. Conclusion Most of the patients switching from original adalimumab were maintained on biosimilar at 6 and 12months of follow-up with similar efficacy and safety as the original drug.

Download Full-text

C-Reactive Protein as a Predictor of Relapse in Asymptomatic Patients with Crohn's Disease

Scottish Medical Journal ◽

10.1177/003693308302800106 ◽

1983 ◽

Vol 28 (1) ◽

pp. 26-29 ◽

Cited By ~ 21

Author(s):

C. André ◽

L. Descos ◽

J. Vignal ◽

J. Gillon

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Acute Phase Proteins ◽

Activity Index ◽

Clinical Status ◽

Disease Activity Index ◽

Serum Levels ◽

C Reactive Protein ◽

Reactive Protein ◽

Asymptomatic Patients

Comparison of the Crohn's Disease Activity Index (CDAI) with serum levels of the acute phase proteins during a 4-year study period of 50 patients with Crohn's disease has shown the serum C-reactive protein (CRP) to be a sensitive indicator of clinical status. Five patients are described in whom raised CRP levels reliably predicted relapse at a time when the patients were asymptomatic and the CDAI was normal. Measurement of serum CRP by radial immunodiffusion is cheap and simple, and if performed frequently in the follow-up of patients with Crohn's disease it may permit earlier, and therefore possibly more effective, treatment of relapse.

Download Full-text

P254 Factors that may predict the need for infliximab optimization in Crohn’s disease

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab076.380 ◽

2021 ◽

Vol 15 (Supplement_1) ◽

pp. S292-S292

Author(s):

C Flores ◽

R Petry ◽

C Bortolin Fonseca ◽

L Dos Santos Harlacher

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Clinical Laboratory ◽

Serum Levels ◽

Therapeutic Drug ◽

C Reactive Protein ◽

Porto Alegre ◽

Reactive Protein ◽

Endoscopic Characteristics ◽

Worse Prognosis

Abstract Background Biological therapy has revolutionized treatment of Crohn’s Disease (CD), increasing the rate of disease remission. Despite this, a significant percentage of patients present partial response or loss of response over time. These patients need optimization of therapy, whether by increasing the dosage or reducing the interval between infusions. The main objective of this study was to identify possible factors related to the need to optimize the dose of infliximab (IFX) in patients with CD. This finding can facilitate the early identification of the need for therapeutic optimization, reducing the risks of unfavorable evolution and decreasing costs related to the disease. Methods Retrospective and prospective maintained database of CD patients under IFX treatment being followed up in the Infusion Center at the Day Hospital of the Hospital de Clínicas de Porto Alegre, Brazil, from 2009 to 2018. Epidemiological, clinical, laboratory and endoscopic characteristics that correlate with worse prognosis of CD were evaluated. The main goal of the study was to identify possible factors related to the need for (IFX) optimization. Results 121 patients were evaluated. Of these, 58 (47,93%) needed the optimization of the IFX dosage. The only variables that had significant statistical difference between the groups with or without need for optimization were anemia (p=0.019) and C reactive protein (CRP) which were persistently elevated in week 14 (p=0.039). After the adjustment with the multivariate model, only the elevated CRP during week 14 was still statistically significant, with a 119% greater risk of optimizing treatment when compared to those of normal CRP. Conclusion Among the factors studied, only the maintenance of higher CRP during week 14 was associated to the need for optimization of the IFX dose. This finding agrees with the literature that describes week 14 as an ideal moment for evaluating the serum levels of immunobiologics as a predictor of sustained response. Thus, in the absence of therapeutic drug monitoring, we could look at persistently high CRP as a marker of the need for therapeutic optimization. This finding needs to be confirmed in prospective studies.

Download Full-text